for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SurModics, Inc.

SRDX.O

Latest Trade

46.74USD

Change

0.75(+1.63%)

Volume

22,466

Today's Range

46.02

 - 

46.75

52 Week Range

38.06

 - 

75.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
45.99
Open
46.02
Volume
22,466
3M AVG Volume
2.23
Today's High
46.75
Today's Low
46.02
52 Week High
75.40
52 Week Low
38.06
Shares Out (MIL)
13.49
Market Cap (MIL)
623.27
Forward P/E
64.77
Dividend (Yield %)
--

Next Event

SurModics Inc Annual Shareholders Meeting

Latest Developments

More

Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial

Surmodics Reports Q3 GAAP Earnings Per Share Of $0.11

Surmodics Q2 GAAP Earnings Per Share $0.09

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SurModics, Inc.

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Industry

Medical Equipment & Supplies

Contact Info

9924 W 74th St

+1.952.5007000

http://www.surmodics.com/

Executive Leadership

Susan E. Knight

Independent Chairman of the Board

Gary R. Maharaj

President, Chief Executive Officer, Director

Timothy J. Arens

Chief Financial Officer, Vice President - Finance, Principal Financial Officer

Thomas A. Greaney

Chief Operating Officer - Medical Devices

Teri Woodwick Sides

Senior Vice President, Chief Marketing Officer

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

1.210

2017

0.510

2018

0.490

2019(E)

0.713
Price To Earnings (TTM)
241.66
Price To Sales (TTM)
6.75
Price To Book (MRQ)
5.25
Price To Cash Flow (TTM)
63.17
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
2.05
Return on Equity (TTM)
1.73

Latest News

BRIEF-Surmodics Says CFO Andrew Lafrence Resigned

* SURMODICS ANNOUNCES LEADERSHIP CHANGE AND APPOINTMENT OF INTERIM CFO

BRIEF-Surmodics Acquires Thrombectomy Technology Assets

* SURMODICS ACQUIRES THROMBECTOMY TECHNOLOGY ASSETS FROM EMBOLITECH, STRENGTHENING PERIPHERAL VASCULAR WHOLE-PRODUCT SOLUTIONS PORTFOLIO

BRIEF-Surmodics Reports Q2 Non-GAAP EPS $0.07

* SURMODICS REPORTS SECOND QUARTER FISCAL 2018 RESULTS, INCREASES FISCAL 2018 GUIDANCE

BRIEF-Surmodics Announces FDA Clearance Of A New .018” Low-Profile Pta Balloon Dilation Catheter

* SURMODICS ANNOUNCES FDA CLEARANCE OF A NEW .018” LOW-PROFILE PTA BALLOON DILATION CATHETER

BRIEF-Abbott And Surmodics Announce Agreement For Next-Generation Drug-Coated Balloon

* ABBOTT AND SURMODICS ANNOUNCE AGREEMENT FOR NEXT-GENERATION DRUG-COATED BALLOON

BRIEF-Surmodics Posts Q1 Adj. Earnings Per Share $0.10

* SURMODICS REPORTS FIRST QUARTER FISCAL 2018 RESULTS, UPDATES FISCAL 2018 GUIDANCE

BRIEF-Surmodics Receives FDA Clearance For Telemark Peripheral Support Microcatheter

* SURMODICS RECEIVES 510(K) CLEARANCE FOR TELEMARK™ CORONARY/PERIPHERAL SUPPORT MICROCATHETER FROM THE U.S. FOOD AND DRUG ADMINISTRATION

BRIEF-Surmodics Q4 gaap earnings per share $0.03

* Surmodics reports fourth quarter fiscal 2017 results and provides fiscal 2018 guidance

BRIEF-Surmodics says received FDA 510(K) and CE mark clearance​

* Surmodics announces global approvals of .014" low-profile pta balloon dilation catheter

BRIEF-Surmodics enters agreement with Baim Institute For Clinical Research​

* Says on August 11 entered into a clinical trial services agreement with Baim Institute For Clinical Research, Inc - sec filing

BRIEF-Surmodics Q3 non-GAAP earnings per share $0.09

* Surmodics reports third quarter fiscal 2017 results and updates fiscal 2017 guidance

BRIEF-Surmodics receives IDE approval to initiate pivotal trial of the surveil™ drug-coated balloon

* Surmodics receives IDE approval to initiate pivotal trial of the surveil™ drug-coated balloon

BRIEF-Surmodics amends and restates its secured revolving credit facility

* On November 2 amended and restated its secured revolving credit facility pursuant to an amended and restated credit agreement

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up